
ResearchusinghematopoieticcellsandothersUSPensioncellshasbeenlimitedinpartbylowefficiencyofgenetransfer(transductionandtransfection)intothesecelltypes.RetroNectinreagentpromotescolocalizationoflentivirusorretroviruswithtargetcellstodramaticallyenhancetransductionefficiency.Asaconsequence,RetroNectinreagentisnowthegoldstandardtransductionenhancerforretroviral/lentiviralgenetransfertohematopoieticcellsandholdsgreatpromiseinclinicalapplication,havingbeenusedforover40clinicaltrials.
Researchusinghematopoieticcellsandothersuspensioncellshasbeenlimitedinpartbylowefficiencyofgenetransfer(transductionandtransfection)intothesecelltypes.RetroNectinreagentpromotescolocalizationoflentivirusorretroviruswithtargetcellstodramaticallyenhancetransductionefficiency.Asaconsequence,RetroNectinreagentisnowthegoldstandardtransductionenhancerforretroviral/lentiviralgenetransfertohematopoieticcellsandholdsgreatpromiseinclinicalapplication,havingbeenusedforover40clinicaltrials.
WhatisRetroNectinreagent?
RetroNectinreagentisarecombinanthumanfibronectinfragment(rFN-CH-296)thatcontainsthreefunctionaldomains:thecell-bindingdomain,theheparin-bindingdomain,andtheCS-1sequence.
HowdoesRetroNectinreagentwork?
RetroNectinenhanceslentiviral-andretroviral-mediatedgenetransductionbyaidingthecolocalizationoftargetcellsandviralparticles.Specifically,virusparticlesbindRetroNectinreagentviainteractionwiththeH-domain,andtargetcellsbindmainlythroughtheinteractionofcellsurfaceintegrinreceptorVLA-5andVLA-4withthefibronectinC-domainandCS-1site,respectively.Byfacilitatingclosephysicalproximity,RetroNectinreagentcanenhanceviral-mediatedgenetransfertotargetcellsexpressingintegrinreceptorsVLA-4and/orVLA-5.VL-4-expressingcellsincludeTcells,Bcells,monocytes,NKcells,eosinophils,bonemarrowmonocyticcells,andlymphoidProgenitors.Thymocytes,activatedTcells,andmastcellsexpressVLA-5.
RetroNectinreagentalsocanbeusedtoenhanceT-cellexpansion(CD8+cells)invitro
T-lymphocyteexpansionfromperipheralbloodmononuclearcells(PBMCs)isusuallyperformedinthepresenceofinterleukin-2(IL-2)andanti-CD3antibodystimulation.TheefficiencyofT-cellexpansioncanbesignificantlyincreasedinthepresenceofRetroNectinreagent.Moreover,theT-cellpopulationafterexpansioninthepresenceofRetroNectinreagentcontainsahighproportionofnaiveTcells.
FAQsregardingproperuseofRetroNectinGMPgrade
- Question:CanIuseTakaraBio"sRetroNectinGMPgradeinclinicaltrials?Answer:Researchersarefreetousethisproductfordevelopmentofresearch-basedclinicaltrials.ProperregulatoryapprovalisrequiredbeforeusingtheGMP-gradeproductinresearch-basedclinicaltrialssincethesetrialsmayrequirespecialconsiderationsormorestringentmanufacturingstandards.
- Question:CanIuseTakaraBio"sRetroNectinGMPgradeforcommercialuse?Answer:ResearchersarefreetousetheproductinaccordancewiththeNoticetoPurchaser,butcommercialuseisnotallowedunderourgeneralTermsandConditionsforpurchaseoftheseproducts.CommercialaccesstotheGMP-gradeproductmaybeavailablethroughaformalLicenseandSupplyAgreement.Inallcases,itistheresearcher’sresponsibilitytogetapprovalfromtheappropriateregulatoryauthoritiesfortheintendeduseoftheseancillarymaterialsforyourapplication.
- Question:CanIuseRetroNectinGMPgradeforinvivoclinicaluse?Answer:No.Theproductcannotbeusedfordirectinvivoapplications.Theproductisintendedforuseasanancillaryreagentinamanufacturingprocesswhichincludesotherstepspriortoanyinvivoapplication.
- Question:IsRetroNectinGMPgrade(#T202)registeredinDMF?Answer:ADMF(18898)wassubmittedfortheliquidformatRetroNectinGMPgradeonMarch15,2019.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
联系电话:010-84492262杨先生
抗原注射进入动物体内后,因为不是一个单独的分子,会随血液循环输送到各处,也就会接触不同的免疫细胞。有些还会被抗原提呈细胞再加工。所以最后的结果是很多个免疫细胞都会接触到。一个抗原分子也有很多抗原表位。每个表位理论上都有能力激活一个B细胞转化为浆细胞。所以体内最后针对该抗原的必定是多克隆
由于动物个体差异的存在,同一抗原免疫同一种系不同个体的动物,产生的抗体的效价有很大的差异.与动物的年龄和营养状况密切相关.免疫用的动物最好选择适龄的健康雄性动物,雌性动物特别是妊娠动物用于制备免疫抗体则非常不合适,有时甚至不产生抗体.
先饲养观察7天其实就是等于隔离检疫,观察一下兔子的身体状况和是否带有其他传染病,淘汰体质多病的个体,防止在免疫过程中死亡或免疫应答不灵敏而不产生抗体.
IgM占血清免疫球蛋白总量的6%,主要存在血管内,是机体受抗原刺激后最先产生的抗体,起“先锋免疫”作用,具有很强的细胞毒活性和细胞溶解活性,由于IgM主要存在在血管内,是抗血管内感染的第一线抗体,对防止败血症的发生有重要作用。
IgG-主力抗体
IgG是初级免疫应答中最持久、最重要的抗体,它仅以单体形式存在。大多是抗菌性、抗毒性和抗病毒抗体属于IgG,它在抗感染中起到主力军作用,它能够促进单核巨噬细胞的吞噬作用(调理作用),中和细菌毒素的毒性(中和毒素)和病毒抗原结合使病毒失去感染宿主细胞的能力(中和病毒)。
IgA-局部抗体
按其免疫功能又分为血清型及分泌型两种。血清型IgA存在于血清中,其含量占总IgA的85%左右。血清型IgA虽有IgG和IgM的某些功能,但在血清中并不显示重要的免疫功能。分泌型IgA存在于分泌液中,如唾液、泪液、初乳、鼻和支气管分泌液、胃肠液、尿液、汗液等。分泌型IgA是机体粘膜局部抗感染免疫的主要抗体。故又称粘膜局部抗体。

